AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Prenetics Global Limited

$23.13 +$7.35 (+46.57%)
NASDAQ · 14 Sep 2026 13:53 UTC
Previous Close
$23.47
Day Range
$22.5$23.19
Year Range
$9.28$27.24
Market Cap
393.21M
AVG Volume
241.37K
Trailing/Forward PE
-5.64/-
PEG ratio
0.11
Dividend Yield
-
Next Earnings Date
2026-11-09
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
050M100M150M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q2142.56M
26 Q1113.75M
25 Q495.11M
25 Q369.04M
25 Q253.26M
25 Q141.52M
24 Q430.62M
24 Q325.41M
24 Q222.51M
24 Q123.08M
Net Income (USD) · TTM
-80M-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-67.61M
26 Q1-71.04M
25 Q4-58.32M
25 Q3-46.55M
25 Q2-49.81M
25 Q1-48.13M
24 Q4-46.3M
24 Q3-46.91M
24 Q2-49.81M
24 Q1-60.89M
Operating Income (USD) · TTM
-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-50.18M
26 Q1-38.33M
25 Q4-39.25M
25 Q3-43.43M
25 Q2-49.07M
25 Q1-49.62M
24 Q4-48.15M
24 Q3-43.04M
24 Q2-44.18M
24 Q1-48.42M
EBITDA (USD) · TTM
-80M-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-62.52M
26 Q1-51.68M
25 Q4-53.16M
25 Q3-53.51M
25 Q2-57.71M
25 Q1-56.83M
24 Q4-55.12M
24 Q3-41.05M
24 Q2-42.08M
24 Q1-45.81M
Cash Flows (USD) · TTM
-40M-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-34.14M
26 Q1-34.14M
25 Q4-22.02M
25 Q30
25 Q20
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
EPS (USD) · TTM
-6-4-2024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-4.16
26 Q1-4.58
25 Q4-4.02
25 Q3-3.56
25 Q2-3.87
25 Q1-3.81
24 Q4-3.71
24 Q3-3.99
24 Q2-4.31
24 Q1-5.49
Expenses (USD) · TTM
-50M050M100M150MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q2119.76M
26 Q1100.25M
25 Q485.54M
25 Q377.79M
25 Q272.91M
25 Q170.89M
24 Q466.29M
24 Q355.47M
24 Q255.98M
24 Q159.84M
Shares Outstanding (USD) · TTM
-20M020M40M60MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PRE Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q241.78M
26 Q112.98M
25 Q40
25 Q3-5.97M
25 Q2-7.36M
25 Q1-6.99M
24 Q4-7.82M
24 Q3-4.84M
24 Q2-7.84M
24 Q1-6.33M
Dividends (USD)
00.20.40.60.8Nov 13Feb 14May 14Aug 14Nov 14Feb 15May 15Aug 15Nov 15Feb 16
PRE Dividends (USD) by quarter
PeriodDividends (USD)
Feb 160.7
Nov 150.7
Aug 150.7
May 150.7
Feb 150.7
Nov 140.67
Aug 140.67
May 140.67
Feb 140.67
Nov 130.64
Employee Count
05001K1.5K20222022202320242025
PRE Employee Count by quarter
PeriodEmployee Count
202598
2024285
2023324
2022400
20221.16K
PE Ratio
706708710712714med 709.77Jul 21Jul 21Aug 21Aug 21Aug 21Aug 21
PRE PE Ratio by quarter
PeriodPE Ratio
Aug 21706.92
Aug 21706.92
Aug 21711.35
Aug 21710.4
Jul 21709.13
Jul 21712.8
Free Cash Flow Yield
-15%-10%-5%0%med 0%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
PRE Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-8.43%
Sep 26-7.77%
Aug 26-7.68%
Aug 26-9.79%
Aug 26-10.18%
Aug 26-11.01%
Jul 26-10.79%
Jul 26-10.73%
Jul 26-10.99%
Jul 26-11.26%
Jul 26-11.88%
Jun 26-10.68%
Jun 26-9.81%
Jun 26-9.29%
Jun 26-6.91%
May 26-6.51%
May 26-8.19%
May 26-8.8%
May 26-8.5%
May 26-8.07%
Apr 26-7.49%
Apr 26-7.7%
Apr 26-7.75%
Apr 26-6.98%
Mar 26-6.7%
Mar 26-7%
Mar 26-6.63%
Mar 26-7.71%
Feb 26-8.12%
Feb 26-8.05%
Feb 260%
Feb 260%
Jan 260%
Jan 260%
Jan 260%
Jan 260%
Jan 260%
Dec 250%
Dec 250%
Dec 250%
Dec 250%
Nov 250%
Nov 250%
Nov 250%
Nov 250%
Oct 250%
Oct 250%
Oct 250%
Oct 250%
Oct 250%
Sep 250%
Sep 250%
Sep 250%
Sep 250%
Aug 250%
Aug 250%
Aug 250%
Aug 250%
Aug 250%
Jul 250%
Jul 250%
Jul 250%
Jul 250%
Jun 250%
Jun 250%
Jun 250%
Jun 250%
May 250%
May 250%
May 250%
May 250%
May 250%
Apr 250%
Apr 250%
Apr 250%
Apr 250%
Mar 250%
Mar 250%
Mar 250%
Mar 250%
Feb 250%
Feb 250%
Feb 250%
Feb 250%
Jan 250%
Jan 250%
Jan 250%
Jan 250%
Jan 250%
Dec 240%
Dec 240%
Dec 240%
Dec 240%
Nov 240%
Nov 240%
Nov 240%
Nov 240%
Nov 240%
Oct 240%
Oct 240%
Price to Sales
12345med 2.86Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
PRE Price to Sales by quarter
PeriodPrice to Sales
Sep 262.84
Sep 263.08
Aug 263.12
Aug 262.45
Aug 262.95
Aug 262.73
Jul 262.78
Jul 262.8
Jul 262.73
Jul 262.67
Jul 262.53
Jun 262.81
Jun 263.06
Jun 263.23
Jun 263.35
May 263.56
May 262.83
May 262.63
May 262.72
May 262.87
Apr 263.09
Apr 263.01
Apr 262.99
Apr 263.32
Mar 263.46
Mar 263.31
Mar 263.49
Mar 263
Feb 262.85
Feb 262.87
Feb 264.42
Feb 263.87
Jan 263.84
Jan 263.71
Jan 263.16
Jan 263.13
Jan 263.18
Dec 253.4
Dec 253.52
Dec 252.99
Dec 252.82
Nov 252.93
Nov 252.55
Nov 252.46
Nov 253.07
Oct 253.69
Oct 254.17
Oct 253.73
Oct 253.45
Oct 253.55
Sep 253.13
Sep 252.98
Sep 252.5
Sep 252.53
Aug 252.39
Aug 252.27
Aug 253.15
Aug 253.08
Aug 253.32
Jul 253.34
Jul 253.28
Jul 253.27
Jul 253.32
Jun 253.52
Jun 253.72
Jun 252.91
Jun 253.45
May 253.86
May 254.28
May 252.61
May 252.24
May 252.2
Apr 252.5
Apr 252.01
Apr 251.8
Apr 251.89
Mar 252
Mar 252.03
Mar 252.26
Mar 252.38
Feb 252.46
Feb 252.67
Feb 252.71
Feb 252.5
Jan 252.63
Jan 252.76
Jan 252.83
Jan 252.72
Jan 252.83
Dec 242.85
Dec 242.83
Dec 242.97
Dec 242.58
Nov 242.24
Nov 242.4
Nov 242.44
Nov 242.5
Nov 242.51
Oct 242.53
Oct 242.77
EV/EBITDA
406080100med 97.15Jul 21Aug 21Sep 21Sep 21Oct 21Nov 21Nov 21
PRE EV/EBITDA by quarter
PeriodEV/EBITDA
Nov 2197.3
Nov 2197.35
Nov 2197.3
Nov 2197.39
Oct 2197.15
Oct 2197.15
Oct 2197.2
Oct 2197.1
Oct 2197.49
Sep 2197.49
Sep 2197.25
Sep 2196.48
Sep 2196.34
Aug 2149.86
Aug 2149.86
Aug 2150.16
Aug 2150.1
Jul 2150.01
Jul 2150.26
Price/Operating Cashflow
020406080med 12.43Apr 22Jun 22Aug 22Oct 22Dec 22Feb 23Apr 23
PRE Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Apr 234
Apr 234.03
Apr 233.88
Apr 234.58
Mar 234.64
Mar 233.58
Mar 233.84
Mar 234.25
Mar 235.03
Feb 234.88
Feb 235.65
Feb 236.86
Feb 237.1
Jan 237.44
Jan 237.49
Jan 238.55
Jan 239.18
Dec 229.66
Dec 2210.15
Dec 2210.92
Dec 228.75
Dec 228.75
Nov 226.23
Nov 227.77
Nov 2210.29
Nov 2210.68
Oct 2210.99
Oct 2212.43
Oct 2212.36
Oct 2212.33
Sep 2212.94
Sep 2212.33
Sep 2212.43
Sep 2214.59
Sep 2213.46
Aug 2216.64
Aug 2216.64
Aug 2216.81
Aug 2216.98
Jul 2217.02
Jul 2217.02
Jul 2216.89
Jul 2217.15
Jul 2216.78
Jun 2217.87
Jun 2217.61
Jun 2219.02
Jun 2221.49
May 2221.83
May 2251.08
May 2271.66
May 2268.69
Apr 2268.97
Apr 2268.69
Apr 2268.76
Apr 2268.69
Apr 2268.21
Mar 2268.38
Mar 2268.62
Mar 2268.55
Mar 2268.62
Price to Book
0246med 1.07Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
PRE Price to Book by quarter
PeriodPrice to Book
Sep 264.36
Sep 264.73
Aug 264.79
Aug 263.75
Aug 262.77
Aug 262.56
Jul 262.62
Jul 262.63
Jul 262.57
Jul 262.51
Jul 262.38
Jun 262.64
Jun 262.88
Jun 263.04
Jun 261.82
May 261.94
May 261.54
May 261.43
May 261.48
May 261.56
Apr 261.68
Apr 261.64
Apr 261.63
Apr 261.81
Mar 261.88
Mar 261.8
Mar 261.9
Mar 261.64
Feb 261.55
Feb 261.57
Feb 261.89
Feb 261.66
Jan 261.65
Jan 261.59
Jan 261.36
Jan 261.34
Jan 261.36
Dec 251.46
Dec 251.51
Dec 251.28
Dec 251.21
Nov 251.25
Nov 251.09
Nov 251.05
Nov 251.08
Oct 251.3
Oct 251.47
Oct 251.32
Oct 251.22
Oct 251.25
Sep 251.1
Sep 251.05
Sep 250.88
Sep 250.65
Aug 250.61
Aug 250.59
Aug 250.56
Aug 250.55
Aug 250.59
Jul 250.6
Jul 250.59
Jul 250.59
Jul 250.59
Jun 250.63
Jun 250.66
Jun 250.52
Jun 250.62
May 250.69
May 250.76
May 250.47
May 250.4
May 250.39
Apr 250.35
Apr 250.28
Apr 250.25
Apr 250.27
Mar 250.28
Mar 250.29
Mar 250.32
Mar 250.34
Feb 250.35
Feb 250.38
Feb 250.38
Feb 250.35
Jan 250.37
Jan 250.39
Jan 250.4
Jan 250.38
Jan 250.4
Dec 240.4
Dec 240.4
Dec 240.42
Dec 240.36
Nov 240.32
Nov 240.28
Nov 240.29
Nov 240.29
Nov 240.3
Oct 240.3
Oct 240.33
Prenetics Global Limited
PRE
Stockpicker

Video analysis: PRE

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: PRE

Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results

globenewswire.com · 26 Aug 2026

Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results

Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham, today announced that Danny Yeung, Chief Executive Officer, and Brian Rosin, Chief Financial Officer, completed open market purchases of the Company's ordinary shares during the period between August 20 and August 25, 2026, within the Company's open trading window following the release of second quarter 2026 financial results. The two executives acquired $1.0 million of shares.

Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth

seekingalpha.com · 24 Aug 2026

Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth

Prenetics Global Limited has achieved explosive growth, reaching 140,000 subscriptions in 20 months, driven by its IM8 supplement and AI-powered marketing. One of the keys to this growth is its marketing mastery, using A/B and multivariate testing to quickly identify the most effective advertising messages. A unique deal with General Catalyst enables PRE to finance up to 70% of customer acquisition costs without equity dilution or debt, amplifying marketing leverage.

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

seekingalpha.com · 22 Aug 2026

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership

globenewswire.com · 20 Aug 2026

Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership

— Lily is IM8's first Global Ambassador from film and television, extending a roster built in elite sport into global entertainment and culture — Lily brings a following of more than 33 million across social platforms and an engagement rate of approximately 5.9%, several times the benchmark for accounts of comparable scale — Partnership lands as Prenetics raises FY 2026 revenue guidance to $220+ million; Initiates FY 2027 revenue guidance of $400+ million — Joins an equity-aligned roster of David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty and Inter Miami CF NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year global partnership with two-time Golden Globe-nominated actress and producer Lily Collins, star and executive producer of Netflix's Emily in Paris. Collins becomes a Global Ambassador of IM8 and a shareholder in Prenetics, demonstrating her long-term conviction in the brand and the Company.

Prenetics Global Q2 Earnings Call Highlights

marketbeat.com · 18 Aug 2026

Prenetics Global Q2 Earnings Call Highlights

Prenetics Global NASDAQ: PRE reported second-quarter revenue of $46.5 million, up 29% sequentially and about 3.9 times from a year earlier, as its IM8 supplement business continued to add subscribers and scale marketing spending. The company raised its full-year revenue outlook and said July marked its first month of positive consolidated adjusted free cash flow, including funding provided under its General Catalyst facility.

Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond

globenewswire.com · 18 Aug 2026

Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond

Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Co

Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director

globenewswire.com · 17 Aug 2026

Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director

30+ years as one of Wall Street's top-ranked equity research consumer analysts, including leadership of U.S. consumer research at UBS Caroline will also serve on the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. Prenetics will report its second quarter 2026 financial results tomorrow, Tuesday, August 18, 2026, and will host a live earnings webcast at 8:30 a.m.

Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation

globenewswire.com · 7 Aug 2026

Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation

Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.